Laurus Labs Share Price Slides Despite Strong Q2 Results After Promoters Sell Shares Worth ₹500 Crore

  • Posted: 16 Nov 2026, 1:54 PM IST
  • 2.5 Min. Read

Laurus Labs Share Price Slides Despite Strong Q2 Results After Promoters Sell Shares Worth ₹500 Crore
Laurus Labs Shares Fall After Promoters Sell 19.63 Lakh Shares Worth ₹500 Crore, Despite Strong Q2 FY27 Earnings.

Laurus Labs shares fell 4.72% on 16 November after promoters sold 19.63 lakh shares worth ₹500 crore. The selling follows a 130% gain in the stock over one year, while Q2 FY27 net profit more than doubled to ₹441 crore.

Laurus Labs share price today fell after the promoters sold shares worth ₹500 crore. The transactions covered nearly 20 lakh shares. The stock was down 4.72% at ₹2,309.70 on the National Stock Exchange (NSE) as of 12:22 pm IST, a fall of ₹114.30 from its previous close of ₹2,424.

The sale involved shares held directly by the promoters and through an investment entity. Exchange data showed that the transactions covered a combined 19.63 lakh shares.

The promoter group had seen a sharp rise in the stock over the past year. Laurus Labs shares had gained around 130% in 12 months and 380% over five years before the latest decline.

The promoters sold shares worth ₹500 crore, which caused the share price of Laurus Labs to drop today. The sale involved two transactions. One covered 14.85 lakh shares held directly by the company's founder and chief executive. Another 4.78 lakh shares were sold through Leven Holdings, which is linked to the executive director and CFO.

The founder's personal holding stood at 15.7 lakh shares, or 0.29% of Laurus Labs, as per the September 2026 shareholding data. Leven Holdings had 62.05 lakh shares, or a 1.15% stake, at the time. Separately, NSN Holdings, represented by the founder, held nearly 23% of the company, or around 12.4 crore shares.

Laurus Labs operates as a Contract Development and Manufacturing Organisation (CDMO), providing drug development and manufacturing services to pharmaceutical companies.

The share sale comes after a strong set of September-quarter results. Laurus Labs reported consolidated net profit of ₹441 crore in Q2 FY27, more than double the ₹195 crore recorded in the corresponding quarter last year.

Revenue from operations increased 33% year-on-year to ₹2,206 crore from ₹1,653 crore. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) rose 78% to ₹762 crore, while the EBITDA margin stood at 34.5%. The company attributed the performance to

growth in its CDMO and Affordable Medicine businesses, along with better capacity utilisation as commercial supplies increased.

The company has also signed agreements to acquire stakes in two businesses. It plans to buy a 60% stake in Canada's Galenvs Science, which specialises in oligonucleotides and precision magnetic nanoparticles. Laurus said the deal would expand its presence in the oligonucleotide market.

It has also agreed to acquire a 52% stake in SI&C Resins, a company focused on peptide-resin technology. The proposed deal is aimed at bringing peptide solid support resins and chromatography stationary phases in-house, strengthening its supply chain and peptide manufacturing capabilities.

Also Read - India Wholesale Inflation Rises to 12.29% in October as Fuel and Power Prices Jump 32.84%

This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer

About the Author
Vishwa Ved
Vishwa Ved

Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.

At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.

When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.